替加环素-阿维巴坦和对照药物对来自全球医疗中心的大量当代嗜麦芽寡养单胞菌分离株的抗菌活性研究。
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
机构信息
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01433-20.
Abstract
Aztreonam-avibactam was tested against 1,839 isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC, 4/4 mg/liter; 97.8% inhibited at ≤8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC, ≤0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC, 0.5/2 mg/liter; 99.5% susceptible) were also very active. Aztreonam-avibactam inhibited 84.7% of non-TMP-SMX-susceptible isolates at ≤8 mg/liter. Aztreonam-avibactam may represent a valuable option for the treatment of infections, addressing a major unmet medical need.
摘要
氨曲南-阿维巴坦对全球收集的 1839 株分离株进行了测试，对来自所有地理区域和感染类型的分离株均显示出强大的活性（总体 MIC，4/4mg/L；97.8%的抑制率在≤8mg/L 时达到）。复方磺胺甲噁唑（TMP-SMX）（MIC，≤0.5/1mg/L；95.4%敏感）和米诺环素（MIC，0.5/2mg/L；99.5%敏感）也非常活跃。氨曲南-阿维巴坦在≤8mg/L 时抑制了 84.7%的非 TMP-SMX 敏感分离株。氨曲南-阿维巴坦可能是治疗感染的一种有价值的选择，满足了一个主要的未满足的医疗需求。
相似文献
1
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01433-20.
2
Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
BMC Microbiol. 2021 Feb 22;21(1):60. doi: 10.1186/s12866-021-02108-2.
3
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.00297-20.
4
Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00777-17. Print 2017 Oct.
5
Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01154-19. Print 2019 Nov.
6
Looking for treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam.
J Chemother. 2023 Nov;35(7):610-613. doi: 10.1080/1120009X.2023.2247199. Epub 2023 Aug 24.
7
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01603-19.
8
Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00559-20.
9
Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
mBio. 2019 Jul 2;10(4):e00405-19. doi: 10.1128/mBio.00405-19.
10
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01856-17. Print 2018 Jan.
引用本文的文献
1
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE).
JAC Antimicrob Resist. 2025 Jul 28;7(4):dlaf131. doi: 10.1093/jacamr/dlaf131. eCollection 2025 Aug.
2
Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review.
Int J Mol Sci. 2025 Jul 18;26(14):6905. doi: 10.3390/ijms26146905.
3
Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to .
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017225. doi: 10.1128/aac.00172-25. Epub 2025 Jun 2.
4
activity of aztreonam-avibactam combination against blood culture isolates of in Japan before the launch of ceftazidime-avibactam.
Microbiol Spectr. 2025 May 6;13(5):e0331624. doi: 10.1128/spectrum.03316-24. Epub 2025 Mar 14.
5
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
6
Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0173624. doi: 10.1128/aac.01736-24. Epub 2025 Feb 7.
7
Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and from Intensive Care Unit and Non-Intensive Care Unit Patients.
Antibiotics (Basel). 2024 Jun 17;13(6):564. doi: 10.3390/antibiotics13060564.
8
Optimizing Antibiotic Therapy for Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach.
Antibiotics (Basel). 2024 Jun 13;13(6):553. doi: 10.3390/antibiotics13060553.
9
Novel case of combination antibiotic therapy for treatment of a complicated polymicrobial urinary tract infection with one organism harboring a metallo-β-lactamase (MBL) in a pregnant patient.
IDCases. 2024 Apr 15;36:e01946. doi: 10.1016/j.idcr.2024.e01946. eCollection 2024.
10
Stenotrophomonas maltophilia in people with Cystic Fibrosis: a systematic review of prevalence, risk factors and management.
Eur J Clin Microbiol Infect Dis. 2023 Nov;42(11):1285-1296. doi: 10.1007/s10096-023-04648-z. Epub 2023 Sep 20.
本文引用的文献
1
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.
J Antimicrob Chemother. 2020 Mar 1;75(3):618-627. doi: 10.1093/jac/dkz497.
2
Growing resistance in Stenotrophomonas maltophilia?
Am J Health Syst Pharm. 2019 Dec 2;76(24):2004-2005. doi: 10.1093/ajhp/zxz247.
3
Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
mBio. 2019 Jul 2;10(4):e00405-19. doi: 10.1128/mBio.00405-19.
4
Antimicrobial Susceptibility of Complex and Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016).
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46. doi: 10.1093/ofid/ofy293. eCollection 2019 Mar.
5
Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
Clin Microbiol Infect. 2019 May;25(5):546-554. doi: 10.1016/j.cmi.2018.11.008. Epub 2018 Nov 16.
6
A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00223-18. Print 2018 Jul.
7
Avibactam Pharmacokinetic/Pharmacodynamic Targets.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02446-17. Print 2018 Jun.
8
An update on β-lactamase inhibitor discovery and development.
Drug Resist Updat. 2018 Jan;36:13-29. doi: 10.1016/j.drup.2017.11.002. Epub 2017 Nov 7.
9
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01856-17. Print 2018 Jan.
10
Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections.
J Glob Antimicrob Resist. 2018 Mar;12:104-106. doi: 10.1016/j.jgar.2017.09.015. Epub 2017 Sep 28.
Zotero 插件